FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL 3235-0287 Estimated average burden hours per response: 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

C/O ARS PHARMACEUTICALS, INC. 11682 EL CAMINO REAL, SUITE 120

 $\mathbf{C}\mathbf{A}$

(State)

92130

(Zip)

(Street) SAN DIEGO

(City)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

					or Sec	ction	30(h) o	f thè Ír	rvestme	nt Cor	mpany Act of	1940			_			_		
						2. Issuer Name and Ticker or Trading Symbol ARS Pharmaceuticals, Inc. [SPRY]									5. Relationship of Reporting Person(s) to Issuer (Check all applicable) John Check John Ch					
(Last) (First) (Middle)					3. Date of Earliest Transaction (Month/Day/Year) 06/04/2024									Office below	er (give title v)		Other below)	(specify		
C/O ARS PHARMACEUTICALS, INC.						4. If Amendment, Date of Original Filed (Month/Day/Year)									6. Individual or Joint/Group Filing (Check Applicable Line)					
11682 EL CAMINO REAL, SUITE 120 (Street)					00/00	06/06/2024									Form filed by One Reporting Person Form filed by More than One Reporting Person					
SAN DIEGO CA 92130				Rule	Rule 10b5-1(c) Transaction Indication															
(City) (State) (Zip)					Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.															
		Table	I - No	n-Deriva	tive S	ecu	rities	Acq	uired,	Dis	posed of,	or E	Bene	ficiall	y Own	ed				
1. Title of Security (Instr. 3) 2. Transact Date (Month/Day						Exed if an	2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transaction Code (Instr. 8)		4. Securities Acquired (A Disposed Of (D) (Instr. 3, 5)			5. Amo Securi Benefi Owned	ties cially I Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)		
									Code	v	Amount	(A) (D)	or	Price	Transa	ction(s) 3 and 4)			(111511.4)	
Common Stock 06/04/2					2024	24		J ⁽¹⁾		2,665,800) I	0	(1)	7,4	90,404		I	By The Pratik Shah Living Trust dated June 15, 2011 ⁽²⁾		
		Та	ble II -								osed of, o				Owne	d				
1. Title of Derivative Security (Instr. 3)	2. Conversio or Exercis Price of Derivative Security		if any		4. Transac Code (li 8)	ction	5. Number tion of		6. Date Exerc Expiration Da (Month/Day/Y		isable and ite ear)	7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. De Se (In	Price of rivative curity str. 5)	9. Number derivative Securities Beneficially Owned Following Reported Transactio (Instr. 4)	Ownershi Form: Direct (D) or Indirec (I) (Instr. 4		Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exercis	able	Expiration Date	Title	Amo or Num of Shar	ber						
1. Name a Shah P		of Reporting Person																		
(Last) (First) (Mic C/O ARS PHARMACEUTICALS, INC. 11682 EL CAMINO REAL, SUITE 120		ddle)																		
(Street) SAN DIEGO		CA	A 9213			-														
(City)		(State)	(Zip))																
		of Reporting Person	d June	e 15, 20	<u>11</u>															
(Last)		(First)	(Mi	ddle)																

Explanation of Responses:

1. The Pratik Shah Living Trust dated June 15, 2011 transferred 1,332,900 shares to The Light Irrevocable Trust #1, of which an adult son of Pratik Shah, M.D. is a beneficiary, and 1,332,900 shares to The Star Irrevocable Trust #1, of which an adult son of Dr. Shah is a beneficiary. Each transfer was made in exchange for trust assets of equal value under an asset substitution power authorized under the terms of each trust.

2. Pratik Shah, Ph.D. is the trustee of The Pratik Shah Living Trust dated June 15, 2011.

Remarks:

The Reporting Persons are filing this amendment solely to replace Footnote 1 in the Form 4 filed on June 6, 2024.

Kathleen Scott, Attorney-in-Fact, for The Pratik Shah Living Trust dated June 15, 2011 Kathleen Scott, Attorney-in-Fact, for Pratik Shah, Ph.D.

Date

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.